Skip to main content
Device Global Header

Subscribe
or Renew

Advanced Search

This article is available to subscribers. Subscribe now. Already have an account? Sign in

PerspectiveFree Preview

Sustainable Discovery and Development of Antibiotics — Is a Nonprofit Approach the Future?

List of authors.
  • Travis B. Nielsen, Ph.D.,
  • Eric P. Brass, M.D., Ph.D.,
  • David N. Gilbert, M.D.,
  • John G. Bartlett, M.D.,
  • and Brad Spellberg, M.D.

Shifting to a nonprofit-driven model for development of antibiotics could encourage discovery and development of truly needed drugs that improve patient outcomes and permit more effective control over the postapproval use of antibiotics to prolong their effectiveness.

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the authors are available at NEJM.org.

This article was published on June 19, 2019, and updated on July 24, 2019, at NEJM.org.

Author Affiliations

From the Stritch School of Medicine and the Parkinson School of Health Sciences and Public Health, Loyola University Chicago, Maywood, IL (T.B.N.); the David Geffen School of Medicine at the University of California, Los Angeles (E.P.B.) and the Los Angeles County and University of Southern California Medical Center (B.S.) — both in Los Angeles; the Providence Portland Medical Center and University of Oregon Health Sciences School of Medicine, Portland (D.N.G.); and the Johns Hopkins University School of Medicine, Baltimore (J.G.B.).

Print Subscriber? Activate your online access.